U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. Accelerating Rare disease Cures (ARC) Program
  1. Center for Drug Evaluation and Research (CDER)

Accelerating Rare disease Cures (ARC) Program

CDER’s ARC Program | Center for Drug Evaluation and Research

CDER’s Accelerating Rare disease Cures (ARC) Program brings together CDER’s collective expertise and activities to provide strategic overview and coordination of CDER’s rare disease activities. The ARC Program is governed by leadership from across CDER's Office of the Center Director, Office of New Drugs, and the Office of Translational Sciences. The program is managed by CDER's Rare Diseases Team.

Vision

Speeding and increasing the development of effective and safe treatment options addressing the unmet needs of patients with rare diseases.

Mission

To drive scientific and regulatory innovation and engagement to accelerate the availability of treatments for patients with rare diseases.

Connect with us!
CDER_ARC_Program@fda.hhs.gov

CDER Rare Disease News



Subscribe

Get email updates on the Accelerating Rare disease Cures Program

Back to Top